Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Exploratory, Self-Controlled Clinical Study of Hetrombopag for Secondary Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

NCT07252375 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT07252375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07252375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Exploratory, Self-Controlled Clinical Study of Hetrombopag for Secondary Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2025
Completion date
November 30, 2028
Enrollment
35 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ctit-chemotherapy induced thrombocytopenia, nasopharyngeal carcinoma (npc)